Syensqo (SYENS) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
26 Feb, 2026Executive summary
Leadership transition with a new CEO focused on accelerating value creation, strategic transformation, and innovation-driven growth.
2025 saw resilient cash generation and margin performance despite challenging demand and macroeconomic conditions, with a focus on cost discipline.
Net sales declined 6–6.5% year-over-year to €5.76bn, mainly due to lower volumes in Electronics, Automotive, and Specialty Polymers, partially offset by growth in Composite Materials and Technology Solutions.
Completed divestment of Oil & Gas business and progressing with Aroma business divestment to sharpen specialty focus.
Free cash flow rose to €356 million, up 60% from 2024, supported by disciplined capital deployment and strong cash conversion.
Financial highlights
Full-year 2025 net sales of €5.76bn, down 6–6.5% year-over-year; organic decline of 3–5%.
Underlying EBITDA was €1.19bn, down 14–14.3% year-over-year, with margin at 20–20.6%.
Gross profit margin for 2025 at 32%, reflecting specialty value proposition.
Free cash flow to shareholders for 2025 at €356 million, 10% above guidance.
Basic EPS for 2025 at €3.72; net profit attributable to shareholders was €381 million, down 31% year-over-year.
Outlook and guidance
2026 expected to see low single-digit volume growth led by Composite Materials, especially civil aerospace, and gradual recovery in semiconductors in H2.
Underlying EBITDA guidance for 2026 at approximately €1.1 billion; operating cash flow expected at €700 million; CapEx below €500 million.
Cost savings of over €200 million targeted by end of 2026 to offset inflation.
Q1 2026 EBITDA expected to be the lowest quarter, similar to Q4 2025.
Foreign exchange is expected to be a €40 million headwind to EBITDA.
Latest events from Syensqo
- Record financials, innovation, and bold sustainability targets defined the meeting.SYENS
AGM 20243 Feb 2026 - Q2 saw sequential growth but year-over-year declines, with CapEx delayed and cash flow hit by settlement.SYENS
Q2 20242 Feb 2026 - Q2 2025 sales and EBITDA fell YoY, but margin gains and stable 2025 outlook were maintained.SYENS
Q2 202521 Jan 2026 - Margins and cash flow held firm despite lower sales, with specialty focus and divestment ongoing.SYENS
Q3 202521 Jan 2026 - 2024 delivered strong cash flow and returns; 2025 targets stable EBITDA and strategic focus.SYENS
Q4 202421 Jan 2026 - Q3 2024 delivered organic growth, margin resilience, and a €300 million buyback launch.SYENS
Q3 202421 Jan 2026 - SSc and HS studies lead a robust pipeline, with major catalysts and data readouts expected in 2025–2026.SYENS
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Strong 2024 results, higher returns, and accelerated innovation amid global challenges.SYENS
AGM 202521 Nov 2025 - Q1 2025 EBITDA down 15% year-over-year; 2025 outlook and cost-saving targets reaffirmed.SYENS
Q1 202519 Nov 2025